gastric protein comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
=== Animal rights === Barker was a vegetarian. In 1982, Barker began ending The Price Is Right episodes with the phrase: "This is Bob Barker reminding you to help control the pet population – have your pets spayed or neutered." Though Barker had already been dabbling in animal rights before meeting Burnet, his efforts became more aggressive during his relationship with her. In 1987, Barker requested the removal of fur prizes for the Miss USA pageant and stepped down as host when the producers refused. In 1989, Barker and United Activists for Animal Rights publicly accused several media projects and the American Humane Association of animal mistreatment and condoning animal mistreatment, a tactic which resulted in a $10 million suit against him and the UAAR for libel, slander, and invasion of privacy. The suit was finally settled by the insurer in 1994. Barker founded DJ&T Foundation in 1994, named after his late wife and mother, which has contributed millions of dollars to animal-neutering programs and funded animal rescue and park facilities all over the United States. In 2004, Barker donated $1 million (equivalent to $1.7 million in 2025) to Columbia Law School to support the study of animal rights. In 2009, Barker wrote a letter about three businesses in Cherokee, North Carolina, asking them to close their bear exhibits. He threatened to not attend the 2009 Game Show Awards, where Barker was to receive a lifetime achievement award, because Betty White would be attending.
== Pathology == Mutations in the PLOD1 gene have been linked to kyphoscoliotic Ehlers–Danlos syndrome (kEDS, in the past EDS VI).Mutations in the PLOD2 gene have been linked to Bruck syndrome in humans. A deficiency in its cofactor vitamin C is associated with scurvy.
== Reception == Halflife received positive ratings, 8 out of 10, from Rock Hard and Metal.de. Likewise, Powermetal.de called it "truly remarkable", a "real pleasure" to listen to as well as a "small masterpiece". Norwegian newspaper Jærbladet gave 5 out of 6 points and recommended it to fans of Anathema, Dark Tranquility, Flowing Tears and Paradise Lost.
=== Sentencing === In 1998, there were wide racial disparities in arrests, prosecutions, sentencing, and deaths. Black people, despite being only 13% of regular drug users, made up for 35% of drug arrests, 55% of convictions, and 74% of people sent to prison for drug possession crimes. Nationwide African-Americans were sent to state prisons for drug offenses 13 times more often than white men. Crime statistics show that in 1999 in the United States, blacks were far more likely to be targeted by law enforcement for drug crimes, and they received much stiffer penalties and sentences than whites. A 2000 study found that the disproportionality of black drug offenders in Pennsylvania prisons was unexplained by higher arrest rates, which suggested the possibility of operative discrimination in sentencing. A 2008 paper stated that drug use rates by blacks (7.4%) were comparable to those by whites (7.2%), and since there are far more whites than blacks, 72% of illegal drug users in America are white, and only 15% are black. According to Michelle Alexander, the author of The New Jim Crow and a professor of law at Stanford Law School, drug trading is done at similar rates all over the US, but most people arrested for it are colored. Together, blacks and Hispanics were 58% of all prisoners in 2008 but only one quarter of the US population. Most prisoners are arrested for drug related crime, and in at least 15 states, three quarters of them are black or Latino.
==== Medical and higher education ==== Martin Luther King Jr./Drew Medical Center in Los Angeles (now Martin Luther King Jr. Outpatient Center) Charles R. Drew University of Medicine and Science in California Charles Drew Health Center in Omaha, Nebraska Charles Drew Science Scholars at Michigan State University Drew Health Foundation in East Palo Alto, California Charles Drew Community Health Center in Burlington, North Carolina Charles Drew Pre-Health Society at the University of Rochester Drew Wellness Center in Columbia, South Carolina Dr. Charles Drew Red Cross Blood and Platelet Donation Center in Washington, D.C. Charles R. Drew Hall at Howard University Charles Drew Memorial Cultural House at Amherst College Charles Drew Premedical Society at Columbia University
Sources: en.wikipedia.org
=== 24-norursodeoxycholic acid === A recent scientific breakthrough for cholestasis that has allowed us to evaluate a new treatment option is that a hydrophilic environment and bicarbonate production protects hepatocytes from bile acid. The novel agent norUDCA (24-norursodeoxycholic acid) can be passively absorbed by cholangiocytes. This leads to bicarbonate production and an environment that is less toxic. Mouse models have found promising results with norUDCA with the drug showing antiproliferative and anti-inflammatory properties. A recent clinical trial found norUDCA had significant dose-dependent reductions for ALP levels. This makes norUDCA a viable possibility to look into as it clearly plays a significant role in the treatment of cholestasis.
=== Signal transduction to the nucleus === PLCγ is a very important enzyme in the pathway as it generates second messenger molecules. It is activated by the tyrosine kinase Itk which is recruited to the cell membrane by binding to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 is produced by the action of phosphoinositide 3-kinase(PI-3K), which phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to produce PIP3. It is not known that PI-3K is activated by the T-cell receptor itself, but there is evidence that CD28, a co-stimulatory receptor providing the second signal, is able to activate PI-3K. The interaction between PLCγ, Itk and PI-3K could be the point in the pathway where the first and the second signal are integrated. Only if both signals are present, PLCγ is activated. Once PLCγ is activated by phosphorylation. It hydrolyses PIP2 into two secondary messenger molecules, namely the membrane-bound diacyl glycerol (DAG) and the soluble inositol 1,4,5-trisphosphate (IP3). These second messenger molecules amplify the TCR signal and distribute the prior localized activation to the entire cell and activate protein cascades that finally lead to the activation of transcription factors. Transcription factors involved in T-cell signaling pathway are the NFAT, NF-κB and AP1, a heterodimer of proteins Fos and Jun. All three transcription factors are needed to activate the transcription of interleukin-2 (IL2) gene.
== Works cited == Bertok L, Chow D (2005). Bertok L, Chow D (eds.). Natural Immunity. Vol. 5 (1st ed.). Elsevier Science. ISBN 978-0-44451-755-5. Breinstrup, Thomas (2006). "Un revolution in le mundo scientific" [A revolution in the scientific world]. Historia de interlingua (in Interlingua). Archived from the original on 2019-04-27. Retrieved 2025-01-14. Chung, Kyung Won (2005). Gross Anatomy (Board Review). Lippincott Williams & Wilkins. ISBN 0-7817-5309-0. Cook, Chad E. (2012). Orthopedic Manual Therapy: An Evidence Based Approach (2nd ed.). Upper Saddle River, NJ: Pearson Education. ISBN 978-0-13-802173-3. Breinstrup, Th.; Stenström, Ingvar; Olsson, Jesper, eds. (2007) [2001]. "Biographias: Ingvar Stenström". Interlingua (in Interlingua). Archived from the original on 2019-04-26. Retrieved 2025-01-15. Dinour, Lauren M. (2019). "Speaking Out on 'Breastfeeding' Terminology: Recommendations for Gender-Inclusive Language in Research and Reporting". Breastfeeding Medicine. 14 (8). Mary Ann Liebert: 523–532. doi:10.1089/bfm.2019.0110. PMID 31364867. Fielding, Lucie (2021). Trans Sex: Clinical Approaches to Trans Sexualities and Erotic Embodiments. New York: Routledge. ISBN 978-0-429-31829-0. Edwards, Heather. "Anatomy Talk". pp. 165–168. Gopsill, Frank Peter (1990). International languages: a matter for Interlingua. Sheffield, England: British Interlingua Society. ISBN 0-9511695-6-4. OCLC 27813762. Gopsill, Frank Peter (1994). Interlingua today: A course for beginners. Sheffield, England: British Interlingua Society. ISBN 978-1-898017-01-1.
Maintaining a healthy weight – Proper nutrition – Regular physical exercise – in addition to helping to maintain a healthy weight, sufficient vigorous physical exercise increases cells' sensitivity to insulin, and can thus prevent and possibly revert insulin resistance. Medication – specific medications have been shown to be able to prevent type 2 diabetes. However, the disease can often be delayed through proper nutrition and regular exercise.
== Selected publications == Steven Ruggles. 2026. The Pig in the Python: U.S. Labor Flows and Economic Opportunity, 1910-2040. Proceedings of the National Academy of Sciences, 123(20): e2601716123. Steven Ruggles. 2025. The Shortcomings of Synthetic Census Microdata for Social Science Research. Proceedings of the National Academy of Sciences, 122(11): e2424655122. Steven Ruggles. 2024. When Privacy Protection Goes Wrong: How and Why the 2020 Census Confidentiality Program Failed. Journal of Economic Perspectives 38(2) 201-226 Steven Ruggles and Diana Magnuson. 2023. 'It’s none of their damn business': Privacy and Disclosure Control in the U.S. Census, 1790-2020. Population and Development Review 49(3): 651-679 Steven Ruggles. 2021. The Revival of Quantification: Reflections on Old New Histories. Social Science History. 45: 1-25. Ruggles, Steven and Diana L. Magnuson. Census Technology, Politics, and Institutional Change, 1790–2020. Journal of American History vol. 107 (2020), pp. 19-51 Ruggles, Steven. Patriarchy, Power, and Pay: The Transformation of American Families, 1800–2015. Demography, vol. 52 (2015), pp. 1797-1823 Ruggles, Steven. Big Microdata for Population Research. Demography, vol. 51 (2014), pp. 287-297 Kennedy, Sheela and Steven Ruggles. Breaking up is Hard to Count: The Rise of Divorce in the United States, 1980–2010.Demography, vol. 51 (2014), pp. 587–598 Ruggles, Steven. Reconsidering the Northwest European Family System. Population and Development Review, vol. 35 (2009), pp. 321–332 Ruggles, Steven.
Sources: en.wikipedia.org
== Role in histo-blood group == The A and B transferases are the foundation of the human ABO blood group system. Both A and B transferases are glycosyltransferases, meaning they transfer a sugar molecule onto an H-antigen. This allows H-antigen to synthesize the glycoprotein and glycolipid conjugates that are known as the A/B antigens. The full name of A transferase is alpha 1-3-N-acetylgalactosaminyltransferase and its function in the cell is to add N-acetylgalactosamine to H-antigen, creating A-antigen. The full name of B transferase is alpha 1-3-galactosyltransferase, and its function in the cell is to add a galactose molecule to H-antigen, creating B-antigen. It is possible for Homo sapiens to have any of four different blood types: Type A (express A antigens), Type B (express B antigens), Type AB (express both A and B antigens) and Type O (express neither A nor B antigens). The gene for A and B transferases is located on chromosome 9. The gene contains seven exons and six introns and the gene itself is over 18kb long. The alleles for A and B transferases are extremely similar. The resulting enzymes only differ in 4 amino acid residues. The differing residues are located at positions 176, 235, 266, and 268 in the enzymes.
The HIV-1 PR precursor catalyzes its own production by facilitating its cleavage from the Gag-Pol polyprotein in a mechanism known as auto-processing. Auto-processing of HIV-1 PR is characterized by two sequential steps: (1) the intramolecular cleavage of the N-terminus at the p6pol-protease cleavage site, which serves to finalize PR processing and increase enzymatic activity with the newly formed PR-reverse transcriptase intermediate, and (2) the intermolecular cleavage of the C-terminus at the protease-reverse transcriptase cleavage site, leading to the assembly of two PR subunits into mature dimers. Dimerization of the two subunits allows for fully functional, combined active site, characterized by two Asp25 catalytic residues (one from each monomer), to form.
=== Gingival crevicular fluid as a biomarker source === For research purposes, utilisation of GCF (gingival crevicular fluid) or PISF (peri-implant sulcular fluid) have been proven to be reliable indicators to examine gingival health, though this is rarely done in clinical practice. Through saliva samples obtained from individuals, the GCF/PISF mixed within saliva have been studied for the level of cytokines and inflammatory mediators. Examples of these mediators include Interleukin (IL) 1-ß, IL-6, macrophage chemotactic protein, interferon g-induced protein 10 (IP-10) and vascular endothelial growth factor (VEGF). Results indicate that individuals with periodontal disease have a significant increase in cytokine count compared to individuals who are of good gingival health. This is explained to be due to the increased interaction between the bacterial biofilm and the cells of the periodontal tissue, leading to heightened diffusion of these mediators along with the GCF into the gingival sulcus.
== Beyond plant disease == Potyvirus RNA codes for at least seven different proteins. One of them is a protease. The TEV protease is a highly site-specific protease that biochemists have used to their advantage to create a protein purification system by incorporating TEV protease's recognition site into protein purification tags. A gene construct is created containing the protein of interest fused to a TEV protease recognition site, followed by an affinity tag, such as a polyhistidine-tag. Following affinity chromatography, the purified protein is then treated with TEV protease. TEV protease cleaves at its recognition site, removing the affinity tag. This allows for affinity purification of proteins that are not well-behaved when fused to protein tags.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.